Modern approaches to prevention and control of cancer of the uterine cervix in women

Journal of the Indian Institute of Science

Volumn 92, Issue 3, 2012, Pages 353-364

  Gupta, S ^a   Kumar, P ^a   Tyagi, A ^a   Sharma, K ^a   Kaur, H ^a   Das, B C ^a  

^a UNIVERSITY OF DELHI   (India)

Author keywords

Cancer stem cell; Cervical cancer; HPV; HPV vaccine; Micro RNA; Screening

Indexed keywords

CANCER STEM CELLS; CERVICAL CANCERS; EARLY CANCER DETECTION; HPV; MALIGNANT TRANSFORMATIONS; MICRO-RNA; PREVENTION AND CONTROLS; PROGNOSTIC SIGNIFICANCE;

DEVELOPING COUNTRIES; DISEASES; ONCOGENIC VIRUSES; RNA; SCREENING; STEM CELLS; VACCINES;

DIAGNOSIS;

EID: 84876271490     PISSN: 09704140     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. IARC. (2008). GLOBOCAN 2008: Cancer Incidence, Mortality and Prevalence Worldwide in 2008. Retrieved June 27, 2012. from http/globocan.iarc.fr/.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D, Global cancer statistics, CA Cancer J Clin, 61(2), 69-90 (2011).
3. Mathew A, George PS, Trends in incidence and mortality rates of squamous cell carcinoma carcinoma and adenocarcinoma of cervix-Worldwide, Asian Pac J Cancer Prev., 10, 645-650 (2009).
4. Vizcaino AP, Moreno V, Bosch FX, et al, International trends in incidence of cervical cancer: II. Squamous-cell carcinoma, Int J Cancer, 86, 429-435 (2000).
5. Shukla S, Bharti AC, Mahata S, Hussain S, Kumar R, Hedau S and Das BC, Infection of human papillomaviruses in cancers of different human organ sites, Indian J Med Res, 130(3), 222-33 (2009b).
6. Das BC, Gopalkrishna V, Hedau S, Katiyar S, Cancer of the uterine cervix and human papillomavirus infection, Curr. Sci., 78(1), 52-63 (2000).
7. Bharti AC, Shukla S, Mahata S, Hedau S and Das BC, Human papillomavirus and cervical cancer control in India, Expert Rev. Obstet. Gynecol, 5(3), 329-346 (2010).
8. Franceschi S, Rajkumar T, Vaccarella S et al, Human papillomavirus and risk factors for cervical cancer in Chennai, India: A case-control study, Int J Cancer, 107 (1), 127-133 (2003).
9. Burchell AN, Winer RL, de Sanjose S, Franco EL, Chapter 6: Epidemiology and transmission dynamics of genital HPV infection, Vaccine, 24 (Suppl. 3), 52-61 (2006).
10. Das BC, Hussain S, Nasare V and Bharadwaj M, Prospects and prejudices of human papillomavirus vaccines in India, Vaccine, 26(22), 2669-79 (2008).
11. Gopalkrishna V, Hedau S, Kailash U, Das BC, Human papillomavirus Type 16 in cancer of the uterine cervix in different geographical regions of India (PS011), Presented at: 18th International papillomavirus Conference, Barcelona, Spain, 23-28 July (2000).
12. Prusty BK, Kumar A, Arora R, Batra S, Das BC, Human papillomavirus (HPV) DNA detection in self-collected urine, Int. J. Gynaecol. Obstet, 90 (3), 223-227 (2005).
13. Laikangbam P, Sengupta S, Bhattacharya P et al, A comparative profile of the prevalence and age distribution of human papillomavirus Type 16/18 infections among three states of India with focus on northeast India, Int. J. Gynecol Cancer, 17(1), 107-117 (2007).
14. Sankaranarayanan R, Nene BM, Dinshaw K, Rajkumar R, Shastri S, Wesley R, Basu P, Sharma R, Thara S, Budukh A and Parkin DM, Early detection of cervical cancer with visual inspection methods: A summary of completed and on-going studies in India, SaludPublicaMex 45 Suppl 3: S399-407 (2003).
15. Das BC, Sharma JK, Gopalakrishna V, Luthra Usha K, Analysis by polymerase chain reaction of the physical state of human papillomavirus Type 16 DNA in cervical preneoplastic and neoplastic lesions, Journal of General Virology, 73 (9), pp. 2327-2336 (1992).
16. NasarQureshi M, Raoul D. Rudelli M.D, Raymond R. Tubbs, Charles V. Biscotti, Lester J. Layfield, Role of HPV DNA testing in predicting cervical intraepithelial lesions: Comparison of HC HPV and ISH HPV, Volume 29, Issue 3, pages 149-155 (2003).
17. Hesselink AT, van den Brule AJ, Brink AA, Berkhof J, van Kemenade FJ, Verheijen RH, et al, Comparison of hybrid capture 2 with in situ hybridization for the detection of high-risk human papillomavirus in liquid-based cervical samples, Cancer, 102, 11-8 (2004).
18. Day SP, Hudson A, Mast A, Sander T, Curtis M, Olson S, et al, Analytical performance of the Investigational Use Only Cervista HPV HR test as determined by a multi-center study, J ClinVirol, 45(Suppl. 1), S63-72 (2009).
19. Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM, A general primer GP5+/ GP6(+)-mediated PCR enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings, J Clin Microbiol, 35, 791-5 (1997).
20. Coutle'e F, Rouleau D, Petignat P, Ghattas G, Kornegay JR, Schlag P, et al, Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping test, J Clin Microbiol, 44, 1998-2006 (2006).
21. Kleter B, van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, terSchegget J et al, Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus, J Clin Microbiol, 37, 2508-17 (1999).
22. Molden T, Kraus I, Skomedal H, Nordstrøm T, Karlsen F, PreTect HPV-Proofer: Real-time detection and typing of E6 / E7 mRNA from carcinogenic human papillomaviruses, J Virol Methods, 142, 204-12 (2007).
23. Jeantet D, Schwarzmann F, Tromp J, Melchers WJ, van der Wurff AA, Oosterlaken T, et al, NucliSENSEasyQ HPV v1 test - testing for oncogenic activity of human papillomaviruses, J Clin Virol, 45(Suppl. 1), S29-37 (2009).
24. Dockter J, Schroder A, Eaton B, Wang A, Sikhamsay N, Morales L, et al, Analytical characterization of the APTIMA HPV Assay, J Clin Virol, 45(Suppl. 1), S39-47 (2009).
25. Schiffman M, Herrero R, Hildesheim A, et al, HPV DNA testing in cervical cancer screening: Results from women in a high-risk province of Costa Rica, Journal of the American Medical Association, 283, 87-93 (2000).
26. Wright TC Jr, Denny L, Kuhn L et al, HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer, Journal of the American Medical Association, 283(1), 81-86 (2000).
27. Gravitt PE, Peyton CL, Apple RJ, and Wheeler, Genotyping of 27 Human Papillomavirus Types by using Li consensus PCR products by single-Hybridization, Reverse line blot detection method, CM. J. Clin Microbiol., 36, 3020-3027 (1998).
28. Gill DK, Bible JM, Biswas C, Kell B, Best JM, Punchard NA, et al, Proliferative T-cell responses to human papillomavirus Type 16 E5 are decreased amongst women with high-grade neoplasia, J Gen Virol., 79, 1971-1976 (1998).
29. Yang DH, Wildeman AG, Sharom FJ. Overexpression, purification, and structural analysis of the hydrophobic E5 protein from human papillomavirus Type 16, Protein Expr Purif., 30, 1-10 (2003).
30. Cattani P, Siddu A, D'Onghia et al, RNA (E6 and E7) assays versus DNA (E6 and E7) assays for risk evaluation for women infected with human papillomavirus, Journal of Clinical Microbiology, 47, 7, 2136-2141 (2009).
31. Lillo FB et al, Determination of human papillomavirus (HPV) load and type in high-grade cervical lesions surgically resected from HPV-infected women during follow-up of HPV infection, Clin Infect Dis., 40, 451-457 (2005).
32. Klaes R, Friedrich T, Spitkovsky D, et al, Overexpression of p16 (INK4 A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri, Int. J. Cancer, 92(2), 276-284 (2001).
33. Dray M, Russell P, Dalrymple C, et al, p16(INK4a) as a complementary marker of high-grade intraepithelial lesions of the uterine cervix. I: Experience with squamous lesions in 189 consecutive cervical biopsies, Pathology, 37(2), 112-124 (2005).
34. Lakshmi S, Rema P and Somanathan T, P16(INK4a) is a surrogatemarker for high-risk andmalignant cervical lesions in the presence of human papillomavirus, Pathobiology, 76 (3), 141-148 (2009)
35. Agoff SN, Lin P, Morihara J, Mao C, Kiviat NB and Koutsky LA, p16(INK4a) expression correlates with degree of cervical neoplasia: A comparison with Ki-67 expression and detection of high-risk HPV types, Modern Pathology, 16 (7), 665-673 (2003).
36. Negri G, Vittadello F, Romano F, et al, P16(INK4a) expression and progression risk of low-grade intraepithelial neoplasia of the cervix uterilVirchowsArchiv, 445 (6), 616-620 (2004).
37. Samarawardana P, et al, p16(INK4a) is superior to highrisk human papillomavirus testing in cervical cytology for the prediction of underlying high-grade dysplasia, Cancer Cytopathology, 118(3), 146 (2010).
38. Cohen DR, Curran T, The structure and function of the fos proto-oncogene, Crit Rev Oncog, 1, 65-88 (1989)
39. Bhupesh K Prusty and Bhudev C Das, Constitutive activation of transcription factor AP-1 in cervical cancer and suppression of human papillomavirus (HPV) transcription and AP-1 activity in HeLa cells by curcumin. Int. J. Cancer, 113, 951-960 (2005).
40. Bhupesh K Prusty, Syed Akhtar Husain and Bhudev C Das, Consitutive activation of nuclear factor kappa B preferential homodimerization of p50 subunits in cervical carcinoma, Frontiers in Bioscience, 10, 1510-1519(2005).
41. Pradip Nair, Kumaravel Somasundaram, Sudhir Krishna, Activated Notch1 Inhibits p53-Induced Apoptosis and Sustains Transformation by Human Papillomavirus Type 16 E6 and E7 Oncogenes through a PI3K-PKB/Akt-Dependent Pathway, J Virol, 77(12), 7106-7112 (2003).
42. Maliekal TT, Bajaj J, Giri V, Subramanyam D and Krishna S, The role of Notch signaling in human cervical cancer: Implications for solid tumors, Oncogene, 27, 5110-5114 (2008).
43. Munger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, Biological activity and molecular targets of human papillomavirus E7 oncoprotein, Oncogene, 20, 788-7898 (2001).
44. Nakano K, Watney E, McDougall JK, Telomerase activity and expression of telomerase RNA component and telomerase catalytic subunit gene in cervical cancer, Am. J. Pathol., 153, 857-864 (1998).
45. Kailash U, Soundararajan CC, Lakshmy R, Arora R, Vivekanandhan S, Das BC, Telomerase activity as an adjunct to high-risk human papillomavirus types 16 and 18 and cytology screening in cervical cancer, Br J Cancer, 95(9), 1250-1257 (2006).
46. Yim EK and Park JS, Biomarkers in cervical cancer, Biomarker Insights, l (1), 215-225 (2007)
47. Kruse AJ, Baak JPA, Janssen EA, et al, Ki67 predicts progression in early CIN: validation of a multivariate progression-risk model, Cellular Oncology, 26(1-2), 13-20 (2004).
48. Kaplanis K, Kiziridou A, Liberis V, Destouni Z, Galazios G, Ecadherin expression during progression of squamous intraepithelial lesions in the uterine cervix, Eur J Gynaecol Oncol, 26(6), 608-10 (2005).
49. Yaldizl M, Hakverdi AU, Bayhan G, Akku Z., Expression of Ecadherin in squamous cell carcinomas of the cervix with correlations to clinicopathological features, Eur J Gynaecol Oncol., 26(1), 95-8 (2005).
50. Yutaka Ueda, Takayuki Enomoto et al, Serum Biomarkers for Early Detection of Gynecologic Cancers, Cancers, 2, 1312-1327 (2010).
51. Uhl-Steidl M, Muller-Holzner E, Zeimet AG, Adolf GR, Daxenbichler G, Marth C, et al, Prognostic value of CD44 splice variant expression in ovarian cancer, Oncology, 52, 400-406 (1995).
52. Das BC, Hussain S, Nasare V and Bharadwaj M, Prospects and prejudices of human papillomavirus vaccines in India, Vaccine, 26(22), 2669-79 (2008).
53. Trottier H, Mahmud S, Prado JC, et al, Type-specific duration of human papillomavirus infection: Implications for human papillomavirus screening and vaccination, J Infect Dis., 197, 1436-47 (2008).
54. Luciano Mariani, Aldo Venuti, HPV vaccine: An overview of immune response, clinical protection, and new approaches for the future., Journal of Translational Medicine, 8, 105 (2010).
55. Ratish Gambhira, Patti E Gravitt, Ioannis Bossis, Peter L Stern, Raphael P Viscidi and Richard BS Roden, Vaccination of Healthy Volunteers with Human Papillomavirus Type 16 L2E7E6 Fusion Protein Induces Serum Antibody that Neutralizes across Papillomavirus Species, Cancer Res, 66, 11120 (2006).
56. Sophia Biemelt, Uwe Sonnewald, Petra Galmbacher, Lothar Willmitzer and Martin Müller, Production of Human Papillomavirus Type 16 Virus-Like Particles in Transgenic Plants, J. Virolvol., 77, 17, 9211-9220 (2003).
57. Mahata S, Bharti AC, Shukla S, Tyagi A, Husain SA and Das BC, Berberine modulates AP-1 activity to suppress HPV transcription and downstream signaling to induce growth arrest and apoptosis in cervical cancer cell, Mol Cancer, 10, 39 (2011).
58. Mahata S, Maru S, Shukla S, Pandey A, Mugesh G, Das BC and Bharti AC, Anticancer property of Bryophyllumpinnata (Lam.) Oken. leaf on human cervical cancer cells, BMC Complement Altern Med 12, 15 (2012).
59. Shukla S, Bharti AC, Hussain S, Mahata S, Hedau S, Kailash U, Kashyap V, Bhambhani S, Roy M, Batra S, Talwar GP and Das BC, Elimination of high-risk human papillomavirus type HPV16 infection by 'Praneem' polyherbal tablet in women with early cervical intraepithelial lesions, J Cancer Res Clin Oncol, 135(12), 1701-9 (2009a).
60. Bharti AC, Shukla S, Mahata S, Hedau S and Das BC, Anti-human papillomavirus therapeutics: Facts & future, Indian J Med Res, 130(3), 296-310 (2009).
61. Xiaoxia Hu, Julie K. Schwarz, James S. Lewis, Jr., Phyllis C. Huettner, Janet S. Rader, Joseph O. Deasy, Perry W. Grigsby, and Xiaowei Wang, A MicroRNA Expression Signature for CervicalCancer Prognosis, Cancer Res, 70(4), 1441-8 (2010).
62. Lui WO, Pourmand N, Patterson BK and Fire A, Patterns of known and novel small RNAs in human cervical cancer. Cancer Res, 67(13), 6031-43 (2007).
63. Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C and Zheng ZM, Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth, PLoS One, 3(7), e2557 (2008).
64. Martinez, AS Gardiner, KF Board, FA Monzon, RP Edwards and SA Khan, Human papillomavirus Type 16 reduces the expression of microRNA-218 in cervical carcinoma cells HPV-16 downregulates miR-21, Oncogene, 27, 2575-2582 (2008).
65. Li Baohua, Hu Ying, Ye Feng; Li Yang, Lv Weiguo, Xie Xing, Reduced miR-34a Expression in Normal Cervical Tissues and Cervical Lesions With High-Risk Human Papillomavirus Infection, International Journal of Gynecological Cancer, 20 (4), 597-604 (2010).
66. Wang X, Wang HK, McCoy JP, Banerjee NS, Rader JS, Broker TR, Meyers C, Chow LT and Zheng ZM, Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6, RNA, 15(4), 637-47 (2009).
67. Singec I, Jandial R, Crain A, Nikkhah G and Snyder EY, The leading edge of stem cell therapeutics, Annu Rev Med, 58, 313-328 (2007).
68. Pardal R, Clarke MF and Morrison SJ, Applying the principles of stem-cell biology to cancer, Nat Rev Cancer, 3, 895-902 (2003).
69. Kondo T, Setoguchi T and Taga T, Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line, Proc Natl Acad Sci USA, 101, 781-786 (2004).
70. Dingqing Feng, Cheng Peng, Cairong Li, Ying Zhou, Min Li, Bin Ling, Haiming Wei and Zhigang Tian, Identification and characterization of cancer stem-like cells from primary carcinoma of the cervix uteri, Oncology Reports, 22, 1129-1134 (2009).
71. Martens JE, Arends J, Van der Linden PJ, De Boer BA and Helmerhorst TJ, Cytokeratin 17 and p63 are markers of the HPV target cell, the cervical stem cell, Anticancer Res, 24, 771-775 (2004).